Companies /Healthcare

Astrazeneca plc

NASDAQ: AZN Drug Manufacturers - General
$187.53
▲ $13.13 (+7.53%) today
Markets open · 1:53pm ET

24/7 Wall St. View

Price Prediction $216.86 +24.3% Our analysts’ 12-month view: target, optimistic case, and floor. AZN price prediction →

AZN at a Glance

Valuation
Market cap
$270.5B
P/E ratio
26.1
Dividend yield
1.91%
Profitability
Revenue (TTM)
$61.4B
Profit margin
17.0%
EPS (TTM)
$6.69
Price
52-week range
$152 – $209
24/7 target
$216.86
Street target
$206.66
Earnings
Next report
Oct 30, 2026

Headquartered in 1 Francis Crick Avenue, Cambridge Fiscal year ends December NASDAQ: AZN astrazeneca.com

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company. It discovers, develops and commercialises prescription medicines in Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), Infectious Disease (V&I) and Rare Disease (via Alexion). Its medicines are sold in more than 125 countries.

Key medicines by area:
- Oncology (roughly half of revenue): Tagrisso, Imfinzi, Imjudo, Calquence, Lynparza, Truqap and Zoladex, plus newer launches Etcamah and Zegfrovy (sunvozertinib, licensed from Dizal). It co-commercialises Enhertu and Datroway with Daiichi Sankyo.
- CVRM: Farxiga, now facing US generics and China VBP, plus Crestor, Lokelma, Wainua and the newly launched Baxfendy.
- R&I: Symbicort, Fasenra, Breztri/Trixeo (moving to a near-zero global warming potential propellant), Saphnelo, Airsupra, Pulmicort and Tezspire (partnered with Amgen).
- Infectious Disease: Beyfortus (partnered with Sanofi) and FluMist.
- Rare Disease: Ultomiris (including add-on Voydeya), Soliris, Strensiq, Koselugo and Kanuma, plus new approvals Klygefa and Amlypave.

Revenue comes from three streams:
- Product Sales.
- Alliance Revenue, which is shares of partners' gross profits and royalties.
- Collaboration Revenue, which is milestones.

Sales are spread across the US, Emerging Markets including China, Europe and Established Rest of World.

The company has more than 180 pipeline projects. It is investing in technologies such as ADCs and AI-driven discovery (insitro, CSPC). It holds a roughly 12.0% equity stake in Summit Therapeutics and opened a new R&D centre in Kendall Square, Massachusetts.

It funds the business through operating cash flow and investment-grade debt (Moody's A1, S&P A+). Net debt was $25.8bn at 30 September 2026. It follows a progressive dividend policy and is pursuing a 2030 growth ambition supported by its Reshaping for Sustainable Growth restructuring programme. Updated

Latest Activity

Biggest movers · At the close
Gainers
  • REGNRegeneron$926.96+13.2%
  • AZNAstraZeneca$186.4+6.9%
  • SPOTSpotify$593.99+6.6%
  • TMUST-Mobile$156.39+6.2%
  • IMOImperial Oil$138.4+5.8%
Losers
  • INTCIntel$65.12-29.3%
  • APPSDigital Turbine$8.9-15.8%
  • SNDKSanDisk$1,149.86-13.6%
  • AAOIApplied Optoelectronics$68.99-12.9%
  • COHRCoherent$209.16-11.8%

Intel closed down 29.27%, the widest single-session move across 380 priority names. Regeneron led the other direction, with chip and optics names filling out the downside.

Read more
Biggest movers · On the open
Gainers
  • REGNRegeneron$914.2+11.7%
  • AZNAstraZeneca$186.72+7.1%
  • TAKTakeda Pharmaceutical$21.21+6.0%
  • GILDGilead Sciences$174.95+5.6%
  • MDLZMondelez International$65.63+5.0%
Losers
  • INTCIntel$65.27-29.1%
  • APPSDigital Turbine$9.26-12.4%
  • MSTRStrategy$125.22-11.6%
  • DOCNDigitalOcean$89.25-10.7%
  • DDOGDatadog$238.8-10.2%

Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.

Read more
AZNAstraZeneca
Q3 2026
EPS
$2.79
est $1.15+143.5%
Revenue
$16.21B
est $16.00B+1.3%

Oncology revenue rose 17%, more than absorbing a 25% drop in Farxiga after US generics arrived, and AstraZeneca still beat EPS expectations. Management reaffirmed full-year guidance and pointed to 2027 readouts.

Quarterly EPS — reported vs estimate
Read more
Pascal Soriot
Earnings · 2026 Q3Pascal SoriotCEO
We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars.

Soriot is putting a dollar figure on AstraZeneca's 2027 catalyst calendar, and it is double what this year's dozen Phase III wins carry. For a $270 billion drugmaker, the pipeline math is now the whole investment case.

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 10/27/26

  • Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
  • Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
  • CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
  • Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.

Read more
Polymarket@polymarket

A 53% cut in death risk versus chemotherapy is the kind of late-stage result that resets an oncology franchise, and it lands after a stretch of pipeline setbacks weighed on the shares. Watch for the full trial data and filing timeline.

BREAKING: AstraZeneca reports major breakthrough in stomach cancer treatment, with its experimental drug reducing the risk of death by 53% compared with chemotherapy in a late-stage trial.
  • Replies24
  • Reposts31
  • Likes237
Read more
Biggest movers · On the open
Gainers
  • INTUIntuit$326.18+5.1%
  • MRSHMarsh$187.37+5.0%
  • AZNAstraZeneca$169.22+4.4%
  • WMTWalmart$121.3+4.4%
  • EXPEExpedia$286.79+4.4%
Losers
  • AAOIApplied Optoelectronics$77.49-10.1%
  • CIFRCipher Digital$9.02-9.3%
  • IRENIren$27.76-9.2%
  • DELLDell Technologies$461.71-9.1%
  • SNDKSanDisk$1,277.91-8.9%

The downside is doing the damage at Wednesday's open: Applied Optoelectronics is off 10.13%, with Dell and SanDisk each shedding roughly 9%. The best gainer, Intuit at 5.07%, does not come close to matching it.

Read more

AZN Coverage

Load More

Frequently Asked Questions

What does AstraZeneca do?

AstraZeneca is a global, science-led biopharmaceutical company. It discovers, develops and commercialises prescription medicines in Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), Infectious Disease (V&I) and Rare Disease (via Alexion).

What is the AZN stock price target?

24/7 Wall St.'s 12-month price target for AZN is $216.86, rated Buy. The Wall Street consensus target is $206.66. AZN price prediction →